ChromaDex Corp., Irvine, CA, has entered a retail commercialization deal with BPI Sports, Hollywood, FL, for its patented lead ingredient, NIAGEN (Nicotinamide Riboside – NR).   
 
Under the terms of the agreement, BPI will have exclusive rights to introduce dietary supplement products featuring NIAGEN in Costco, Walmart, Walgreens, Target, Miejer, Kroger, Publix, Vitacost, QVC, Home Shopping Network, Shopko, Ahold, eVine Live, Ulta, and Wegmans.
 
BPI Sports plans to market the ingredient under the trade names “ANTI AGING PILL,” “LIFE1,” “CELL1” and “ENEDREX.” 

Frank Jaksch Jr., founder and CEO of ChromaDex, commented “BPI Sports has had tremendous success in selling their sports nutrition products into major retailers. Given BPI’s established retail distribution and marketing presence, I believe this relationship will result in a rapid and significant increase in the availability of products containing NIAGEN at thousands of nationwide retail locations. The story of NIAGEN as the vitamin of healthy aging is starting to become better known. As awareness builds, it is important that consumer products featuring NIAGEN are readily available.”
 
James Grage, VP and co-founder of BPI Sports, commented, “This ingredient is the first ever commercially available product specifically marketed as an NAD+ Booster and as such, has the potential for both Anti-Aging and Weight Management in ingestible form. NIAGEN represents real ground breaking science in terms of true life healthspan. It also illustrates BPI Sports continuing to use (NDIN) ingredients at a time when compliance within the industry is at the forefront. The fact that we have secured rights for NIAGEN exclusivity in many of the top retailers is great news to the consumer. We will be responsible for making this lesser-known form of vitamin B3 affordable and available at the retail consumer level. This partnership and exclusivity for NIAGEN will set us apart from independent brokers and sellers while enabling us to make a significant difference in the marketplace almost overnight. There are so many health benefits linked to NIAGEN and we look forward to sharing them with the rest of the world.”
 
ChromaDex’s NIAGEN is the only commercially available form of NR and is supported by five patents issued and several pending, with patents rights acquired from Cornell University, Dartmouth College and Washington University. In addition to human clinical studies, ChromaDex is actively collaborating with numerous leading universities and research institutes studying the health benefits of NIAGEN.